TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
NCT00985049
Recruiting
Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemia. This will be compared to blood gene expression in blood cells and analyzed with the patients' genetic profile. This might allow us to assess the amount of inflammation that occurs when patients are... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
08/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Diseases
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +841 locations
Conditions: Multiple Myeloma
Register for Updates
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
NCT05264623
Recruiting
This will be a multicenter, prospective, open label, non-randomized, single arm 12 month study, evaluating the safety and effectiveness of the TECHNOLAS TENEO 317 Model 2 (Software version "1.28 US") excimer laser when used in LASIK surgery to treat hyperopia with or without hyperopic astigmatism. Both eyes of a subject may be enrolled so long as both eyes meet all inclusion/exclusion requirements. Analysis of the primary effectiveness endpoint will be completed at refractive stability.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
08/21/2024
Locations: Site 113, Newport Beach, California +11 locations
Conditions: Hyperopia
Register for Updates
AMPLIFY Study: Transcutaneous Spinal Direct Current Stimulation to Enhance Locomotor Rehabilitation After SCI
NCT05700942
Recruiting
Locomotor training (LT) facilitates recovery of spinal locomotor networks after incomplete spinal cord injury (ISCI), but walking impairments persist. A limitation of LT is insufficient excitation of spinal locomotor circuits to induce neuroplastic recovery. Transcutaneous spinal direct current stimulation (tsDCS) is a non-invasive approach to increase spinal excitation and modulate spinal reflexes. The study will examine if tsDCS combined with LT enhances locomotor rehabilitation after ISCI.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2024
Locations: Brooks Rehabilitation Hospital, Jacksonville, Florida
Conditions: Spinal Cord Injuries
Register for Updates
Group Preconception Care for Fertility Patients
NCT05924464
Recruiting
Group Preconception Care for Fertility Patients aims to translate the well-established group prenatal care model to preconception care to improve pregnancy and neonatal outcomes. In partnership with Pomelo Care (a virtual maternity care program), the investigators are conducting this study using couples at Penn Fertility Care.
Gender:
FEMALE
Ages:
All
Trial Updated:
08/21/2024
Locations: Penn Reproductive Research Unit, 3701 Market Street, Suite 810, Philadelphia, Pennsylvania
Conditions: Infertility
Register for Updates
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
NCT06265285
Recruiting
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery
NCT06502002
Recruiting
This will be a randomized, placebo-controlled, double-blinded, pilot trial with two parallel groups (1:1 ratio) receiving either dexmedetomidine (initial bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or upon reaching maximum dose of 2mcg/kg, whichever comes first) or placebo (normal saline as a bolus followed by maintenance infusion at the same rate of the intervention group). Dexmede... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Surgery-Complications, Respiratory Complication, Lung Injury, Acute
Register for Updates
Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
NCT01258231
Recruiting
This study aims to identify genetic causes of adverse events after cardiac surgery, such as atrial fibrillation, myocardial infarction, renal dysfunction and heart failure. Patients undergoing heart surgery at Brigham and Women's Hospital and Texas Heart Institute are eligible to participate.
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
08/21/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Heart; Dysfunction Postoperative, Cardiac Surgery, Genetic Predisposition to Disease, Atrial Fibrillation, Myocardial Infarction, Heart Failure
Register for Updates
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04598009
Recruiting
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +1 locations
Conditions: Melanoma Stage III, Melanoma Stage IV
Register for Updates
Food Delivery, Remote Monitoring, and Coaching-Enhanced Education for Optimized Diabetes Management (FREEDOM)
NCT05288452
Recruiting
Brief Summary: The FREEDOM study aims to develop a scalable intervention to improve type 2 diabetes mellitus control in low-income Black adults in the Deep South. The intervention targets social determinants of health (SDoH) such as reduced healthcare access, poverty, transportation barriers, and food insecurity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: UAB Hospital and UMMC Cardiology Clinics, Birmingham, Alabama
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT05732103
Recruiting
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Mayo Clinic Arizona, Phoenix, Arizona +3 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
NCT05945849
Recruiting
The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack your AML cells. The first treatment is a modified stem cell transplant, using blood-forming stem cells donated from a healthy donor. From the same donor, we will also make CAR T-cells, which are leukemia fighting cells, which will be given to the pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Leukemia, Myeloid, Acute
Register for Updates